Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction

Toxicological Sciences

Volumn 135, Issue 2, 2013, Pages 451-464

  Yanochko, Gina M ^a   Vitsky, Allison ^a   Heyen, Jonathan R ^a   Hirakawa, Brad ^a   Lam, Justine L ^b   May, Jeff ^a   Nichols, Tim ^a   Sace, Frederick ^a   Trajkovic, Dusko ^a   Blasi, Eileen ^a  

^a Irisys Research and Development   (United States)

^b PFIZER INC   (United States)

Author keywords

Fibroblast growth factor receptor; Fibroblast growth factor 23; Klotho; Mineralization; Phosphate; Vitamin D

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PD 0330361; PHOSPHORUS; SODIUM PHOSPHATE COTRANSPORTER 2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART RATE; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERPHOSPHATEMIA; KIDNEY; MINERALIZATION; NONHUMAN; RAT; SOFT TISSUE; TUMOR CALCINOSIS;

FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR-23; KLOTHO; MINERALIZATION; PHOSPHATE; VITAMIN D.;

ANIMALS; BASE SEQUENCE; CARDIOVASCULAR SYSTEM; CELL LINE; DNA PRIMERS; FIBROBLAST GROWTH FACTORS; HUMANS; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84886475220     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft161     Document Type: Article

References (43)

1. Andrukhova, O., Zeitz, U., Goetz, R., Mohammadi, M., Lanske, B., and Erben, R. G. (2012). FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51, 621-628.
2. Avivi, A., Yayon, A., and Givol, D. (1993). A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 330, 249-252.
3. Beenken, A., and Mohammadi, M. (2009). The FGF family: Biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235-253.
4. Beer, H. D., Vindevoghel, L., Gait, M. J., Revest, J. M., Duan, D. R., Mason, I., Dickson, C., and Werner, S. (2000). Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs thatis preferentially expressed in the skin and the brain. J. Biol. Chem. 275, 16091-16097.
5. Bergwitz, C., and Jüppner, H. (2010). Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu. Rev. Med. 61, 91-104.
6. Biber, J., Hernando, N., Forster, I., and Murer, H. (2009). Regulation of phosphate transport in proximal tubules. Pflugers. Arch. 458, 39-52.
7. Blasi, E., Heyen, J., Patyna, S., Hemkens, M., Ramirez, D., John-Baptiste, A., Steidl-Nichols, J., and McHarg, A. (2012). Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. Cardiovasc. Ther. 30, 287-294.
8. Brooks, A. N., Kilgour, E., and Smith, P. D. (2012). Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin Cancer Res. 18, OF1-OF8.
9. Brown, A. P. (2010). Development of serum calcium and phosphorus as clinical biomarkers for drug-induced systemic mineralization: Case study with a MEK inhibitor. In Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing (Shayne C. Gad, Ed.), pp. 1-22. John Wiley and Sons, Inc. New Jersey.
10. Brown, A. P., Courtney, C., Carlson, T., and Graziano, M. (2005a). Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis. Toxicologist 90, 108.
11. Brown, A. P., Courtney, C. L., King, L. M., Groom, S. C., and Graziano, M. J. (2005b). Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol. Pathol. 33, 449-455.
12. Cabebe, E., and Wakelee, H. (2007). Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat. Options Oncol. 8, 15-27.
13. Cancilla, B., Davies, A., Cauchi, J. A., Risbridger, G. P., and Bertram, J. F. (2001). Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 60, 147-155.
14. Chellaiah, A. T., McEwen, D. G., Werner, S., Xu, J., and Ornitz, D. M. (1994). Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/ FGF-1. J. Biol. Chem. 269, 11620-11627.
15. Datta, K., Graziano, M. J., and Courtney, C. L. (2003). Toxicity of the fibroblast growth factor inhibitor, PD 176067, in juvenile and adult dogs. Toxicologist 72, 386.
16. Diaz, D., Allamneni, K., Tarrant, J. M., Lewin-Koh, S. C., Pai, R., Dhawan, P., Cain, G. R., Kozlowski, C., Hiraragi, H., La, N., et al. (2012). Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney. Toxicol. Sci. 125, 187-195.
17. Farrow, E. G., Davis, S. I., Summers, L. J., and White, K. E. (2009). Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20, 955-960.
18. Faul, C., Amaral, A. P., Oskouei, B., Hu, M. C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011). FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393-4408.
19. Fletcher, A. M., Bregman, C. L., Woicke, J., Salcedo, T. W., Zidell, R. H., Janke, H. E., Fang, H., Janusz, W. J., Schulze, G. E., and Mense, M. G. (2010). Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition. Toxicol. Pathol. 38, 267-279.
20. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M. L., Goetz, R., Mohammadi, M., and Baum, M. (2009). FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Renal Physiol. 297, F282-F291.
21. Gattineni, J., and Baum, M. (2010). Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): Implications for disorders of phosphate metabolism. Pediatr. Nephrol. 25, 591-601.
22. Heyen, J. R., Blasi, E. R., Nikula, K., Rocha, R., Daust, H. A., Frierdich, G., Van Vleet, J. F., De Ciechi, P., McMahon, E. G., and Rudolph, A. E. (2002). Structural, functional, and molecular characterization of the SHHF model of heart failure. Am. J. Physiol. Heart Circ. Physiol. 283, H1775-H1784.
23. Jonker, D. J., Rosen, L. S., Sawyer, M. B., de Braud, F., Wilding, G., Sweeney, C. J., Jayson, G. C., McArthur, G. A., Rustin, G., Goss, G., et al. (2011). A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann. Oncol. 22, 1413-1419.
24. Jono, S., McKee, M. D., Murry, C. E., Shioi, A., Nishizawa, Y., Mori, K., Morii, H., and Giachelli, C. M. (2000). Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87, E10-E17.
25. Kim, K. B., Chesney, J., Robinson, D., Gardner, H., Shi, M. M., and Kirkwood, J. M. (2011). Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin. Cancer Res. 17, 7451-7461.
26. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997). Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45-51.
27. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K. P., Baum, M. G., Schiavi, S., Hu, M. C., Moe, O. W., et al. (2006). Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 281, 6120-6123.
28. Li, H., Martin, A., David, V., and Quarles, L. D. (2011). Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am. J. Physiol. Endocrinol. Metab. 300, E508-E517.
29. Liu, S., Vierthaler, L., Tang, W., Zhou, J., and Quarles, L. D. (2008). FGFR3 and FGFR4 do not mediate renal effects of FGF23. J. Am. Soc. Nephrol. 19, 2342-2350.
30. Neves, K. R., Graciolli, F. G., dos Reis, L. M., Pasqualucci, C. A., Moysés, R. M., and Jorgetti, V. (2004). Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int. 66, 2237-2244.
31. Ohnishi, M., Nakatani, T., Lanske, B., and Razzaque, M. S. (2009). Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 75, 1166-1172.
32. Olauson, H., Lindberg, K., Amin, R., Jia, T., Wernerson, A., Andersson, G., and Larsson, T. E. (2012). Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J. Am. Soc. Nephrol. 23, 1641-1651.
33. Ranch, D., Zhang, M. Y., Portale, A. A., and Perwad, F. (2011). Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J. Bone Miner. Res. 26, 1883-1890.
34. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., and Yamashita, T. (2004). Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561-568.
35. Sitara, D., Razzaque, M. S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R. G., Jüppner, H., and Lanske, B. (2004). Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23, 421-432.
36. Sitara, D., Razzaque, M. S., St-Arnaud, R., Huang, W., Taguchi, T., Erben, R. G., and Lanske, B. (2006). Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 169, 2161-2170.
37. Stockham, S. L., and Scott, M. A. (2008). Urinary system. In Fundamentals of Veterinary Clinical Pathology, 2nd ed., pp. 415-494. Blackwell Publishing, Ames, IA.
38. Thachil, J. (2011). Nitric oxide and adverse events of vascular endothelial growth factor inhibitors. Curr. Med. Res. Opin. 27, 1503-1507.
39. Touchberry, C. D., Green, T. M., Tchikrizov, V., Mannix, J. E., Mao, T. F., Carney, B. W., Girgis, M., Vincent, R. J., Wetmore, L. A., Dawn, B., et al. (2013). FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am. J. Physiol. Endocrinol. Metab. 304, E863-E873.
40. Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 10, 116-129.
41. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., and Yamashita, T. (2006). Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774.
42. Vitsky, A., Li, G., Sace, F., Liu, L., John-Baptiste, A., May, J., Wong, T., Venne, P., and Blasi, E. (2011). Phosphate dysregulation following pan-FGFR inhibition in rodents. Vet. Pathol. 48, E1, 209 (Abstract).
43. Zhang, M. Y., Ranch, D., Pereira, R. C., Armbrecht, H. J., Portale, A. A., and Perwad, F. (2012). Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153, 1806-1816